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Abstract
The latency and reactivation ofMycobacterium tuberculosis infection has been well stud-
ied. However, there have been few studies of the latency and reactivation ofMycobacte-
rium avium complex (MAC), the most common etiological non-tuberculousMycobacterium
species next toM. tuberculosis in humans worldwide. We hypothesized that latent MAC
infections can be reactivated following immunosuppression after combination chemother-
apy with clarithromycin and rifampicin under experimental conditions. To this end, we
employed a modified Cornell-like murine model of tuberculosis and investigated six strains
consisting of two type strains and four clinical isolates ofM. avium andM. intracellulare.
After aerosol infection of each MAC strain, five to six mice per group were euthanized at 2,
4, 10, 18, 28 and 35 weeks post-infection, and lungs were sampled to analyze bacterial bur-
den and histopathology. One strain of each species maintained a culture-negative state for
10 weeks after completion of 6 weeks of chemotherapy, but was reactivated after 5 weeks
of immunosuppression in the lungs with dexamethasone (three out of six mice inM. avium
infection) or sulfasalazine (four out of six mice in bothM. avium andM. intracellulare infec-
tion). The four remaining MAC strains exhibited decreased bacterial loads in response to
chemotherapy; however, they remained at detectable levels and underwent regrowth after
immunosuppression. In addition, the exacerbated lung pathology demonstrated a correla-
tion with bacterial burden after reactivation. In conclusion, our results suggest the possibility
of MAC reactivation in an experimental mouse model, and experimentally demonstrate that
a compromised immune status can induce reactivation and/or regrowth of MAC infection.
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Introduction
Nontuberculous mycobacteria (NTM) are widely spread in environment which may cause pul-
monary disease, skin and soft tissue infections, lymphadenitis, and disseminated disease
among which, chronic pulmonary disease is the most commonly found in clinical condition [1,
2]. NTM lung diseases are becoming more prevalent worldwide [3, 4], and the most common
etiological agent of MTM lung disease isMycobacterium avium complex (MAC) which con-
sists ofMycobacterium avium andMycobacterium intracellulare [1, 2]. Since NTM are ubiqui-
tous in the environment and frequently isolated from both soil and water, humans could
occasionally encounter these organisms. Nevertheless, it is generally believed that NTM infec-
tions are effectively controlled by normal host defense mechanism [5]. Thus, it is believed that
several unknown susceptibility factors might affect the healthy individuals to develop the NTM
lung disease [6].
Although analogous to tuberculosis (TB) within several ways, the natural pathogenesis of
NTM infection is unknown. Likewise, it is still on debate whether NTM lung disease develops
soon after infection or, like TB, develops after a period of latency. In humans, NTMmay cause
both symptomatic disease and asymptomatic infection, and previous skin test studies suggested
that a substantial proportion have had prior and presumably asymptomatic NTM infection [7, 8].
As well as TB, NTM disease has emerged as important infectious complications in patients
receiving tumor necrosis factor (TNF) antagonists [9–11]. It was suggested that the develop-
ment of TB after TNF antagonist therapy is a reactivation of latent TB infection (LTBI) caused
by immunosuppression [12, 13]. Moreover, recent studies have reported that TNF antagonist
therapy is also a predisposing factor for NTM infection [9–11]. Together, these findings raise
the possibility of latent NTM infection. However, unlike TB, the concept of 'latent' NTM infec-
tion is controversial and there is no solid scientific evidence of latent NTM infection. Moreover,
there have been no experimental studies on ‘latent’ NTM infection due to a lack of suitable ani-
mal models. The Cornell model was developed to investigate the LTBI using by a murine model,
in which mice infected withM. tuberculosis are treated with anti-TB drugs, resulting in an
absence of detectable bacilli by in organ culture [14, 15]. Reactivation of bacilli was spontane-
ously occurred from this culture-negative state following immunosuppression. Here, we investi-
gated the possibility of reactivation of MAC infection using the Cornell-like murine model.
Materials and Methods
Ethics statement
All animal experiments were performed in accordance with the Korean Food and Drug
Administration (KFDA) guidelines. The experimental protocols used in this study were
reviewed and approved by the Ethics Committee and Institutional Animal Care and Use Com-
mittee (Permit Number: 2012-0072-2) of the Laboratory Animal Research Center at Yonsei
University College of Medicine (Seoul, Korea). Carbon dioxide (CO2) was used for euthanasia.
Mice
Specific pathogen-free 5- to 6-week-old female C57BL/6 mice were purchased from Japan SLC,
Inc. (Shijuoka, Japan). Mice were maintained under barrier conditions in a BL-3 biohazard ani-
mal facility at the Yonsei University Medical Research Center with constant temperature (24
±1°C) and humidity (50±5%). Animals were fed a sterile commercial mouse diet and provided
with water ad libitum under standardized light-controlled conditions (each 12 hours of light
and dark period). Mice were monitored daily, and none of mice exhibited any clinical symptom
or illness during this experiment.
Experimental Reactivation of MAC in a Cornell-Like Murine Model
PLOS ONE | DOI:10.1371/journal.pone.0139251 September 25, 2015 2 / 14
additional role in the study design, data collection and
analysis, decision to publish, or preparation of the
manuscript. The specific role of this author is
articulated in the ‘author contributions’ section.
Competing Interests: Co-author Won-Jung Koh is
employed by Samsung Medical Center. There are no
patents, products in development, or marketed
products to declare. This does not alter the authors’
adherence to all the PLOS ONE policies on sharing
data and materials.
Chemicals and reagents
Antibiotics (clarithromycin and rifampicin) and immunosuppressant agents (dexamethasone
and sulfasalazine) were purchased from Sigma Chemical Co. (St Louis, MO, USA). Middleb-
rook 7H9 broth, 7H10 agar substrate and oleic acid-albumin-dextrose-catalase (OADC) were
purchased from Difco Laboratories (Detroit, MI, USA) and Becton Dickinson (Sparks, MD,
USA), respectively.
Bacterial strains, cultures and preparation of mycobacterial single cell
suspensions
A total of six MAC strains consisting of both type strains and clinical strains were used in this
study. Briefly, two types of strains,M. avium (MAV) 104 andM. intracellulare (MI) ATCC
13950, were obtained from the American Type Culture Collection (ATCC, Manassas, VA). In
addition, we used four clinical isolates, MAV SM #1, MAV SM #22, MI SM #30, andMI SM #42,
which were recovered from patients who met the diagnostic criteria of NTM lung disease, accord-
ing to the American Thoracic Society and Infectious Diseases Society of America guidelines [2]
(Samsung Medical Center, Seoul, Korea) [16, 17]. All strains used in this study showed a smooth
colony type with the exception of MAV SM#22, which displayed a rough colony morphotype.
The identity of MAC isolates was identified by rpoB sequencing analysis, MACmultiplex PCR
[18] and hsp65 code sequevar analysis [19]. Susceptibility of eachMAC strains was measured
according to the Clinical and Laboratory Standards Institute (CLSI) guidelines [20]. Since there is
no correlation between in vitro susceptibility results for anti-tuberculosis agents such as rifampi-
cin, ethambutol and rifabutin, susceptibility was evaluated on the basis of clarithromycinMIC
only [2, 20]. All strains used in this study were found to be susceptible (MICs of 8 μg/mL).
All strains were initially cultured in 7H9 broth supplemented with 10% (vol/vol) OADC for
2 weeks at 37°C with shaking. The strains showed no apparent difference in growth and colony
forming time on 7H10-OADC agar. Single-cell suspensions of cultured bacteria were prepared
as previously described [21] and quantified by plating on 7H10-OADC agar. Briefly, mycobac-
terial cells grown in 7H9-OADC were harvested by centrifugation at 10,000 × g for 20 min, and
then washed three times with 10 mM phosphate-buffered saline (PBS; pH 7.2). Mycobacterial
cell pellets were homogenized using an overhead stirrer (Wheaton Instruments, Millville, NJ,
USA) for 1 min on ice to minimize cell clumping. The homogenized mycobacterial cells were
passed through an 8-μm pore size filter (Millipore Corp., Bedford, MA, USA). The presence of
predominantly single cells in the final preparation was confirmed by acid-fast staining. Seed
lots of each strain were stored in small aliquots at −80°C until use. Before conducting the infec-
tion study, ten-fold serial dilutions from seed lots were plated on 7H10 agar plates to quantify
the number of organisms per milliliter.
In vivo infection protocol
For the animal infection study, C57BL/6 mice were infected with each MAC strain via the Cor-
nell model described by McCune et al. with minor modifications [22]. Briefly, each group of
6-week-old C57BL/6 mice was given an aerogenic infection with one of the MAC strain for 60
min in the inhalation chamber of an airborne infection apparatus (Glas-Col, Terre Haute, IN,
USA) in a BL-3 biohazard animal room. Alternatively, control mice were inoculated with an
equal volume of sterile PBS. For initial dose measurement, mice were killed one hour after
infection and lungs were removed aseptically, homogenized, and plated. Five to six mice per
group were euthanized at 2, 4, 10, 18, 28 and 35 weeks post-infection, and their lungs were col-
lected for bacteriological and histopathological examinations (Fig 1).
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Treatment with antibiotics and immunosuppressants
A schematic of the experimental procedure used in this study is depicted in Fig 1. At 10 weeks
post-infection, when stable infections of MAC were established in the lung, infected mice
began to receive daily treatment with clarithromycin (200 mg/kg of body weight) and rifampi-
cin (10 mg/kg of body weight) by oral gavage for a period of 6 weeks. Bacterial counts were
taken from the lungs of mice at 2 weeks and again after completion of 6 weeks of chemotherapy
to confirm clearance of cultivable organisms. At 28 weeks post-infection and, 12 weeks after
the completion of chemotherapy, the treated mice received intraperitoneal injections of 200 μl
of dexamethasone or sulfasalazine at 10 mg/kg of body weight every 2 days for 5 weeks (from
26 to 31 weeks post-infection). At 35 weeks post-infection and, 2 weeks after completion of
immunosuppression therapy, the treated mice were euthanized and examined.
Definition of “reactivation” and “regrowth”
The term “reactivation” refers to reactivation of latent TB. The definition of latent TB is evi-
dence of infection such as a positive tuberculin skin test (TST) or IFN-γ release assay, without
clinical symptoms or culturable bacilli in the sputum [23]. In this study, we used the term
“reactivation” when the bacilli reappeared from a culture-negative state. Likewise, the term
“regrowth” was used when there were countable bacilli after chemotherapy and relapse was
observed after immune suppression.
Bacterial counts
Five to six mice per group were euthanized at 2, 4, 10, 18, 28 and 35 weeks post-infection with
CO2, and lungs were homogenized in a 0.04% Tween 80 saline solution using a tissue grinder
(Wheaton, NJ, USA) with an automatic homogenizing stirrer (Daihan Scientific, Seoul, South
Korea). The number of viable bacteria in the tissue suspension was determined by plating serial
dilutions of the organ homogenates onto Middlebrook 7H11 agar supplemented with 10%
OADC. Colonies were counted after incubation for 2 to 4 weeks at 37°C, and the limit of bacte-
rial detection was determined as 25 CFU per whole lung after completion of antibiotic treat-
ment (18 weeks).
Fig 1. Schematic experimental procedure utilizing a modified Cornell-like mousemodel.Mice were infected with each MAC strain by aerosol route.
Ten weeks after infection, mice were treated with clarithromycin and rifampicin for six weeks. At 28 weeks post-infection, which was 12 weeks after
completion of chemotherapy, mice received immunosuppressants for 5 weeks as described in Materials and Methods. Mice were euthanized and lungs were
collected for bacteriological and histopathological examination at the time points depicted by arrows.
doi:10.1371/journal.pone.0139251.g001
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Histopathological analysis
For histopathological analysis, lung from the mice was excised and fixed for overnight in 10%
normal buffered formalin. The tissues were trimmed into cassettes and embedded with paraf-
fin. Each tissue blocks were cut into 4mm thick, and then mounted on microscopic slides. Sec-
tions were stained with hematoxylin and eosin (H&E) and examined for histopathological
lesions. The level of inflammation in the lungs of the mice was evaluated using ImageJ software
(National Institutes of Health, MD, USA), as previously described [24].
Statistical analysis
The resultant values for bacterial counts were reported as the median ± interquartile range
(IQR) and lung inflammation values were reported as the mean ± standard deviation (SD).
The significance was determined by the Kruskal-Wallis test followed by Dunn’s test for bacte-
rial count, and unpaired t-tests for inflammation values using statistical software (GraphPad
Prism Software V5.0; GraphPad Software, San Diego, CA). Values of P< 0.05, P< 0.01 or
P< 0.001 were considered to be statistically significant.
Results
Bacteriological evaluation ofMycobacterium avium complex reactivation
Bacterial counts of two clinical strains, MAV SM#1 and MI SM#42, decreased to an undetect-
able level after 18 weeks, which was after six weeks of antibiotics treatment (Fig 2A and 2B).
Undetectable bacterial counts were maintained until the beginning of immunosuppressant
treatment in all mice of these two groups. For the MAV SM#1 infected group, four out of six
mice exhibited reactivation of bacteria after sulfasalazine treatment, and three out of six mice
exhibited bacterial reappearance after dexamethasone treatment (Fig 2C). For the MI SM#42
infected group, four out of six mice had reappearance of bacterial counts after sulfasalazine
treatment, and which were higher than that of the initial infection, whereas no mice had reap-
pearance of bacteria after dexamethasone treatment (Fig 2D). One of the six mice infected with
MAV SM#1 had bacterial reappearance without immunosuppression, suggesting the possibil-
ity of spontaneous reactivation. However, none of the MI SM#42 infected mice exhibited reac-
tivation without immunosuppression. Interestingly, the reactivated bacterial count in MI
SM#42 infected mice increased at a faster rate and was higher compared with the bacterial
count before chemotherapy.
Bacteriological evaluation ofMycobacterium avium complex regrowth
The bacterial counts of twoM. avium strains, MAV 104 and MAV SM#22, were decreased at
week 18 following 6 weeks of antibiotic treatment, but remained within detectable limits (Fig
3A and 3B). On the other hand, the bacterial counts at week 28 were slightly increased com-
pared to the counts obtained prior to immunosuppressant treatment. The bacterial counts
after immunosuppressant treatment exhibited a more rapid increase compare to MAV 104
infected mice that did not receive immunosuppression therapy (P< 0.01). Interestingly, there
were no significant differences between the immunosuppressant-treated and untreated mice
infected with MAV SM#22. The bacterial counts of the other twoM. intracellulare strains, MI
ATCC13950 and MI SM#30, showed similar patterns of regrowth as theM. avium regrowth
model (Fig 3C and 3D). However, there was no significant difference in bacterial counts
between the groups treated with sulfasalazine or dexamethasone.
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Histopathological evaluation of theM. avium-infected lungs
Histopathological staining showed inflamed regions ofM. avium-infected lungs. Specifically,
H&E staining results showed an almost complete disappearance of inflammation was observed
for the antibiotic treated lungs of MAV SM#1 infected mice at week 28 (Figs 4A and 5A), and a
significant decrease (P< 0.05) inflammation with antibiotics-treated lungs compared to
untreated lungs that were infected with MAV 104 (Figs 4A and 5B). The antibiotics-treated
lungs that were infected with MAV 104 and MAV SM#22 showed reappearance of regions of
inflammation without any further immunosuppressant treatment at week 35 and the magni-
tude of inflammation was significantly increased (P< 0.001) following treatment with either
sulfasalazine or dexamethasone (Figs 4A, 5B and 5C). Interestingly, histopathology of MAV
SM#22 infected lungs revealed significant inflammation after immune suppression, although
the bacterial count in the lung remained the same. In the case of antibiotic treated lungs with
previous MAV SM#1 infection, no significant occurrence of inflammation was detected with-
out immunosuppressant treatments, while an obvious increase in inflammation was detected
after immunosuppressant treatment (Figs 4A and 5A).
Fig 2. Reactivation ofMycobacterium avium complex in the lungs of mice following immunosuppression.Mice were infected with approximately
500–1,000 CFUs of each MAC strain for 10 weeks and treated for 6 weeks with clarithromycin and rifampicin. Following the antibiotic regimen, mice were
treated with immunosuppressants. A: MAV SM#1 represents the reactivation model ofM. avium strains. B: MI SM#42 represents the reactivation model ofM.
intracellulare strains. Both graphs depict a dramatic decrease in bacterial counts, which were undetectable after antibiotic treatment and a dramatic increase
after sulfasalazine treatment. For A and B, CFUs at 35 weeks represent the sulfasalazine-treated group. C and D represent the bacterial counts of individual
murine lungs infected with MAV SM#1 and MI SM#42, respectively. Each group exhibited different reactivation levels according to the immunosuppressant
used. The dashed line represents the detection limit of bacterial counts. Red arrows represent undetectable bacilli in each mouse. For A and B, the data are
the median ± interquartile range (IQR).
doi:10.1371/journal.pone.0139251.g002
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Histopathological evaluation of theM. intracellulare-infected lungs
Histopathological staining showed inflamed regions ofM. intracellulare-infected lungs (. The
antibiotics-treated lung with previous MI SM#42 infection did not exhibit reoccurrence of
inflammation without immunosuppressant treatment; however, significantly increased
(P< 0.001) inflammation was detected after immunosuppressant treatment (Figs 4B and 6A).
H&E staining results revealed no significant decreases of inflammation regions in the antibiot-
ics-treated lungs compared to untreated lungs infected with MI ATCC13950 and MI SM#30.
On the other hand, inflammation in the antibiotic treated lungs infected with MI SM#42 was
almost completely absent at week 28 (Figs 4B and 6A). The infection of MI ATCC13950 and
MI SM#30 lungs treated with antibiotics showed continuous regions of inflammation without
further treatment at week 35, and the magnitude of inflammation was significantly increased
(P< 0.001) compared to the initial infections after treatment with sulfasalazine or dexametha-
sone (Figs 4B, 6B and 6C).
Discussion
LTBI, a primary concern in the treatment of TB, has been investigated by numerous research-
ers using various animal models. However, there have been few studies on latent MAC
Fig 3. Regrowth ofMycobacterium avium complex in the lungs of mice following immunosuppression. A: MAV104 and B: MAVSM#22 are the
regrowth models ofM. avium strains. C: MI ATCC13950 and D: MI SM#30 are the regrowth models ofM. intracellulare strains. All graphs show a dramatic
decrease in bacterial counts, although they remained detectable after antibiotic treatment with clarithromycin and rifampicin. The number of bacterial counts
showed dramatic increase after dexamethasone and sulfasalazine treatment. The dashed line represents the detection limit of bacterial counts. The data are
the median ± interquartile range (IQR). **P < 0.01 compared to no immunosuppression group. n.s., not significant.
doi:10.1371/journal.pone.0139251.g003
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infections, even though the symptoms of pulmonary MAC infection are quite analogous to
those of TB. Evidence for the existence of MAC recurrence is relatively recent, and its patho-
genesis has not been studied as well as that of TB. Recently, there have been several case reports
suggesting the possibility of MAC reactivation based on the genomic identity between initial
isolates and recurrent isolates after chemotherapy [25, 26]. In addition, a population-based
national survey in the United States revealed that positive result rates for MAC skin tests peak
in young adults and decrease in older populations [7]. Nevertheless, MAC-associated lung dis-
ease is generally considered to be most common in the elderly [1, 2]. Researchers have specu-
lated that these findings may be related to the existence of a latency as well as emaciating of the
immune system with age, which could explain both the lower positive rate of MAC skin test
and the higher rate of NTM-related lung disease [7]. Likewise, the development of NTM-
related lung disease shortly after TNF antagonist treatment has provided further evidence for
the possibility of latent MAC infection [9–11]. However, it has not yet been confirmed
Fig 4. Lung inflammation values in mice. Lung inflammation values are presented as the mean
percentage of the area of inflammation from lung infection of five to six mice per group (±standard deviation).
At 28 weeks and 35 weeks post infection, lung samples from each mouse were analyzed as described in the
Materials and Methods. The inflamed areas were significantly increased after immunosuppression.
*P < 0.05, ***P < 0.001, n.s., not significant.
doi:10.1371/journal.pone.0139251.g004
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experimentally whether or not MAC infection can enter a latent state. In light of this current
state, we hypothesized that MAC can cause latent infection, and confirmed this hypothesis by
observing reactivation of MAC infections in the Cornell-like murine model [14, 15].
In the present study, bacterial count results and histopathological analysis of lungs sug-
gested that the reactivation of MAC can occur under a compromised immune system (systemic
immunosuppression). MAV SM#1- and MI SM#42-infected mice appeared to be successfully
treated with antibiotics since the bacteria counts were decreased to an undetectable level. How-
ever, most of the mice, that were thought to have undergone bacterial clearance presented with
a dramatically increased number of bacterial counts after immunosuppressant treatment.
Although there were differences in the rate of reactivation depending on bacterial strain and
type of immunosuppressant, it is quite reasonable to assume that the bacteria had gone into a
latent phase and were reactivated following compromise of the immune system, since there
were no other sources of mycobacterial infection in these mice. In addition, our results suggest
a model of regrowth for some MAC strains that do not respond well to antibiotics typically
used for MAC-associated disease. Indeed, the remaining bacteria in some animals exhibited
significant regrowth after antibiotic treatment following immunosuppressant treatment, exhib-
iting a faster rate of regrowth compared to immunocompetent animals (Fig 3).
There are no reported standardized protocols for establishing latency of TB within the Cor-
nell model, and outcomes can vary depending on experimental parameters such as the myco-
bacterial strain used, inoculating dose, route of infection, infection period, concentration of
Fig 5. Histopathology of lungs inM. avium-infectedmice. A: MAVSM#1 represents the reactivation model and B: MAV104 and C: MAVSM#22 are the
regrowth models ofM. avium strains. (a) Untreated controls and (b) antibiotic-treated samples at 28 weeks post infection. Histopathological changes of lungs
withM. avium infection at 35 weeks post infection with no immunosuppression (c), sulfasalazine treatment (d), and dexamethasone treatment (e). The scale
bar represents 1 mm.
doi:10.1371/journal.pone.0139251.g005
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antibiotics, length of treatment and the post-antibiotic rest periods [27]. Thus, we employed sev-
eral clinical isolates of MAV andMI in this study. As expected, the different strains exhibited
different in vivo growth kinetics although they showed similar growth kinetics in vitro. This dif-
ference in in vivo growth kinetics, which might reflect differences in host-pathogen interactions,
may have affected responses to the same antibiotic treatment. As a result, we were able to define
two groups of reactivation and regrowth in terms of presence of cultivable bacilli after treatment
with antibiotics. Macrolides are primarily recommended as part of a therapeutic regimen for
MAC lung disease [2]. Although rifampicin is known to affect the metabolism of clarithromycin
resulting in decreased serum concentrations of the latter [28], we selected clarithromycin and
rifampicin according to the standardized combination antibiotic therapy used in humanMAC
disease [2]. However, in this study we failed to induce a culture-negative state for two strains of
MAC. We were unable to clarify the concentration of antibiotics and the length of treatment for
the sterilized MAC due to a lack of reference studies using this combination of antibiotics in a
mouse model followed by aerosol infection. Thus, it is possible that these factors may have con-
tributed to different rates of bacterial clearance after antibiotic treatment.
With respect to the route of infection, we chose an aerosol infection route, which has been
shown to facilitate bacterial colonization in the lung and subsequent proliferate within the tis-
sue [29]. While infection through the intravenous route elicits a systemic immune response in
the host and is less pathogenic in a murine TB model [30], pathologic lung lesions do not
Fig 6. Lung Histopathology ofM. intracellulare infectedmice. A: MI SM#42 represents the reactivation model. B: MI ATCC13950 and C: MI SM#30 are
the regrowth models of the indicatedM. intracellulare strains. (a) Untreated controls and (b) antibiotic-treated samples at 28 weeks post infection.
Histopathological changes of the lungs withM. intracellulare infection at 35 weeks post infection with no immunosuppression (c), sulfasalazine treatment (d),
and dexamethasone treatment (e). The scale bar represents 1 mm at ×10 magnification.
doi:10.1371/journal.pone.0139251.g006
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appear in murineMycobacterium abscessusmodels [31]. As we aimed to induce lung patho-
logic lesions corresponding to bacterial load at different time points in this study, we chose an
aerosol infection route. We found that most of the mice infected by aerosol route with MAC
did not exhibit bacterial dissemination to spleen by 10 weeks post-infection (prior to antibiotics
treatment), although similar patterns of MAC regrowth in the spleen and lungs were observed
after immunosuppression (S1 and S2 Figs). Thus, we focused on bacterial burden and histopa-
thology of the lungs which is the organ most remarkably affected by MAC aerosol infection.
In this study, we used dexamethasone and sulfasalazine for immune suppression. Dexa-
methasone is a glucocorticoid immunosuppressant that is commonly used to induce reactiva-
tion of latent TB in Cornell-like animal models. However, to the best of our knowledge, this
study is the first use of sulfasalazine as an immunosuppressant for mycobacterial reactivation.
Interestingly, sulfasalazine-treated mice showed a higher reactivation rate compared to dexa-
methasone-treated mice with 66.7% and 50.0% observed for MAV SM#1 infection, and 66.7%
and 0% for MI SM#42 infection, respectively. As these two immunosuppressants have different
mechanisms of action, further investigation of the differences in immunological events after
treatment with these agents may provide clues for detailed immunological mechanisms of reac-
tivation for the different MAC strains.
In spite of the variations observed for the Cornell-like murine model, we successfully
removed the bacteria in at least one strain of each MAC species by antibiotic treatment and
induced reactivation after immune suppression. Since MAC are ubiquitously distributed in the
environment and are frequently encountered by individuals who receive skin tests or receive
TNF antagonist therapy, the skin test results or TNF antagonist treatment cannot be consid-
ered direct evidence of latent MAC infection. In addition, a previous study demonstrated latent
MAC infection in simian immunodeficiency virus-infected rhesus macaques [32]. However,
the findings of that study were limited by the fact that the monkeys were housed outdoors and
the source of infection was not identified [32]. To avoid this limitation, we fully controlled all
sources of MAC infection during our study except for the first intentional aerosol infection,
and achieved the reactivation of MAC after immune suppression followed by chemotherapy.
Therefore, reactivation from a latent state of MAC infection is possible explanation for our
observation. Moreover, our data showed that the rapid regrowth of MAC in immunocompro-
mised mice was consistent with the general concept that the host immune systems are impor-
tant in controlling MAC infection.
The Cornell murine model was originally adopted to understand some aspects of latency
and reactivation of TB after these processes were firstly and clinically proven in humans. Here
we employed this Cornell-like murine model to investigate the reactivation of MAC, since
whether or not MAC bacilli exist in a truly latent form in humans remains an open question.
One recent clinical study reported that reinfection with new MAC genotypes is a common
cause of recurrence of MAC infection [33] and that a quarter of recurrences were true relapses
after completion of therapy. Although it is extremely difficult to distinguish whether cases of
true relapse resulted from reinfection with the same genotype or from reactivation of latent
infection, our study experimentally presented the possibility of endogenous reactivation of
MAC from a latent state due to fundamental blockade of other sources of MAC infection. Nev-
ertheless, as the latency and reactivation of MAC has not yet been verified in a natural host,
our study has several limitations. Specifically, lack of additional evidence of a latent state such
as changes in gene expression in MAC and changing patterns of cytokine expression in the
host should be investigated in future studies. Moreover, detection of latent state MAC by the
plating assay may not have been ideal for cultivating antibiotic-injured bacteria or viable but
non-culturable bacteria. To differentiate between undetectable bacilli and non-culturable states
it might be useful to verify the presence of bacterial RNA in apparently sterilized tissues after
Experimental Reactivation of MAC in a Cornell-Like Murine Model
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completion of antibiotic treatment. Nevertheless, TST is still used as a standard method for
diagnosing latent TB as nucleic acid amplification tests or acid-fast staining of bacilli are not
recommended for diagnosis of latent TB because of their low sensitivity [34, 35]. In the case of
TB, the latency was first clinically verified and has been studied widely in experimental settings
such as the Cornell model. Although MAC latency and reactivation is not clinically established,
the potential for MAC reactivation could not be excluded based on our experimental results.
In summary, our study highlights the possibility for relapse of MAC pulmonary infection
resulting from reactivation of a latent infection. In addition, our results demonstrate that an
immune-compromised status can serve as a key trigger to induce reactivation of latent MAC
infection in an experimental mouse model.
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